Urinary Tract and Genital Infections in Patients With Type 2 Diabetes Treated With Sodium-Glucose Cotransporter 2 Inhibitors

Date: 
November, 2016

November 12, 2016. This meta-analysis of randomized controlled trials (RCTs) evaluated the risk of urinary tract infection (UTIs) and genital infection in patients with type 2 diabetes using sodium-glucose cotransporter 2 (SGLT-2) inhibitors. A total of 52 RCTs involving 36,689 patients were eligible for inclusion, and all drug formulations and dosages were evaluated. Investigators found that patients receiving canagliflozin, dapagliflozin, and empagliflozin had a higher risk of genital infections vs placebo, with odds ratios ranging from 3.21 (95% CI 2.08-4.93) for dapagliflozin 2.5 mg to 5.23 (95% CI 3.86-7.09) for canagliflozin 300 mg. Only dapagliflozin 10 mg was associated with significantly higher rates of UTIs vs placebo, and dapagliflozin was the only SGLT-2 inhibitor that showed a dose-response risk for UTIs and genital infections.